Cocrystal Pharma Inc (COCP)

Cocrystal Pharma's stock price decreased by 55.81% between November 25, 2024, and November 24, 2025, with a 52-week range of $0.90 to $3.26. On August 14, 2025, the company reported its Second Quarter 2025 financial results, including a net loss of $4.4 million. CDI-988 was selected for an oral presentation at the 9th International Calicivirus Conference in September 2025. In October 2025, Cocrystal Pharma received a $500,000 NIH SBIR award. On November 14, 2025, the company announced its Third Quarter 2025 financial results, reporting an EPS of -$0.19, and the stock drifted 12.5% lower over 8 days. The share price was $0.96 on November 24, 2025, and $1.01 as of November 27, 2025.

The search results do not explicitly discuss demand seasonality, but the nature of its business in developing antiviral therapeutics suggests potential seasonality. Demand for influenza-related antivirals would likely be higher during the winter months. The company's focus on emerging viral threats could also introduce demand fluctuations based on outbreak patterns.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics, operating within the Healthcare sector, specifically in Drug Discovery. The company utilizes structure-based technologies to create antiviral drugs targeting serious viral diseases. Key product candidates include CC-42344, an oral PB2 inhibitor for influenza A, CDI-988, an oral pan-viral protease inhibitor for noroviruses and COVID-19, and CC-31244, a broad-spectrum replication inhibitor for Hepatitis C.

Cocrystal Pharma, Inc. is headquartered in Bothell, Washington, USA, with an additional office in Miami, Florida, USA. The company also has a subsidiary, Cocrystal Pharma Australia, Pty LTD, located in Melbourne, Australia.

Information specifically detailing Cocrystal Pharma's brand reputation is not readily available. The company's reputation is likely tied to its progress in clinical trials and scientific advancements in antiviral drug development.

Cocrystal Pharma's ownership is a mix of institutional, retail, and individual investors. Institutional owners held 733,319 shares as of September 30, 2025, with major shareholders including Vanguard Group Inc., Renaissance Technologies Llc, and Geode Capital Management, Llc. Individual insiders own approximately 34% of the company's shares, with top shareholders including Phillip Frost, Fred Hassan, and Raymond Schinazi. The general public holds approximately 60.9% of the company's shares.